NCT06072196View on ClinicalTrials.gov

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

CompletedOBSERVATIONAL
Enrollment

3,017

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Prostatic Neoplasms
Interventions
DRUG

Novel hormonal therapy

As provided in real-world setting

Trial Locations (1)

10001

Pfizer Inc, New York

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Pfizer

INDUSTRY